












































Grade3，下痢 Grade4，好中球減少 Grade4（nadir は day17の10/µL），血小板減少 Grade4，
敗血症，DIC となり多臓器不全にて永眠された．併用薬は異なるが 2 レジメンとも同様の経
過を辿ったことからカペシタビンによる有害事象であった可能性が高く，短期間の内服で重
















入院時内服薬：セルトラリン 50㎎　1 日 1 回　
夕食後，エチゾラム 0.5㎎　1 日 1 回　夕食後，ク
ロチアゼパム  5 ㎎　1 日 1 回　昼食後，エソメプ
ラゾール 20㎎　1 日 1 回　夕食後．
経過（カペシタビン＋オキサリプラチン併用療
法）：Day2 に食欲不振と倦怠感が出現し，day3 に
Grade3 へ悪化したため day3 夕よりカペシタビ
ンを中止した．カペシタビン内服期間は 2 日間で











DIC 加療を追加した．口内炎は day14に Grade3
























1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 (day)
WBC Neut
WBC(/μL) 8460 10680 1100 1120 580 680 390 350 410 480 770 2320 6230 21950
Neut(/μL) 5067 6897 552 359 80 19 10 9.8 20 40 143 789 15628
PLT(万/µL) 33.2 29.8 5.2 3.4 1.7 3.1 1.9 1.6 1.5 1.5 2.0 3.0 4.3 6.8
Hb(g/dL) 13.5 14.1 15.1 14.5 12.2 11.7 10.9 11.2 11.0 11.5 11.9 12.9 12.3 12.7
CRP(㎎/dL) 0.04 2.9 6.2 12.8 15.6 22.0 24.5 27.5 28.8 28.8 27.5 22.5
maxBT(℃) 36.7 36.6 36.5 36.8 36.5 36.7 36.1 36.9 36.5 37.5 37.9 38.2 37.3 37.9 36.7 36.7 36.2 36.8 36.7 36.2 36.8
便回数 1 0 0 1 2 1 0 1 0 6 5 15 15 13 20 20 20 22 0 2 1
口内炎 G1 G1 G2 G2 G2 G3 G3 G3 G3 G3 G2 G2






























シタビン内服期間は 5 日間であった．Day8 より
口内炎が出現し day12に Grade3 へ悪化した．口
唇腫脹，口腔内出血，嚥下痛，会話困難となる程
の著明な症状が現れた．また day14から 1 日約40
行 の Grade3 下 痢 と な っ た．血 液 学 的 毒 性 は
day14に Grade4 好中球減少となり，day17に10/µL

































1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
WBC Neut PLT
WBC(/μL) 6960 8250 4130 1720 1320 480 420 180
Neut(/μL) 4197 6221 2213 700 180 20 20 10
PLT(万/μL) 55.8 39.2 4.7 2.5 1.1 1.2 0.4 0.4
Hb(g/dL) 11 12.1 13.8 13.7 13.5 12.9 12.5 12.6
CRP(㎎/dL) 0.04 0.2 0.2 3.2 25.5
maxBT(℃) 36.7 36.6 36.5 36.6 36.4 36.3 36.6 36.6 36.9 36.5 36.4 36.3 36.2 36.8 36.5 36.5 36.6
便回数 2 0 0 1 0 2 2 3 6 3 2 3 6 40 40 10 8
口内炎 G1 G2 G2 G2 G3 G3 G3 G3 G3 G3



































目頃より Grade3 の重篤な下痢や口内炎が発症し， 






















　Lu らの報告では，5-FU の投与により PBMC 中
の DPD 活 性 が 平 均 の 30％以 下 の 患 者 で は
Grade2 ～3 の重篤な有害事象が発現し，平均の10
％以下の患者は全例死亡した17）．また完全欠損型
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　The case was about a 45-year-old man. The 
combination therapy of capecitabine + oxaliplatin 
was introduced for HER2-positive esophagogastric 
junction cancer. Due to loss of appetite, adminis-
tration of capecitabine was discontinued after two 
days. The patient subsequently developed grade 
3 stomatitis, grade 3 diarrhea, grade 4 neutro-
penia （nadir was 9.8/µL on day 17）, grade 4 
thrombocytopenia, and febrile neutropenia; but 
symptoms were alleviated by medical treatment. 
The dose of capecitabine was reduced by one step, 
the regimen was changed to trastuzumab + 
capecitabine, and chemotherapy was resumed. Yet, 
capecitabine was discontinued after 5 days of its 
administration due to loss of appetite and fatigue. 
Thereafter, the patient developed grade 3 
stomatitis, grade 4 diarrhea, grade 4 neutropenia 
（nadir was 10/µL on day 17）, grade 4 thrombo-
cytopenia, sepsis and disseminated intravascular 
coagulation （DIC）; and subsequently died of 
multiple organ failure. These two regimens 
followed the same course although the concomi-
tant medications were different; hence, the patient 
was likely to have experienced an adverse event 
caused by capecitabine and may have had the 
intolerance of capecitabine given the manifesta-
tion of severe symptoms following the short-term 
oral administration. Furthermore, dihydropy-
rimidine dehydrogenase （DPD） deficiency may 
also be suspected. Thus, it would be necessary to 
fully explain the patient with the existence of these 
symptoms in mind and to inform the medical staff 
about the risks when administering a fluoro-
pyrimidine anticancer drug.
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